HER2 0, HER2 1+and HER2 2+/FISH Negative Primary Breast Cancers Are Biologically Distinct

被引：0
|
作者：
Donahue, Nolan [1 ]
Aragao, Alessa [2 ]
Gordezky, Rachel [3 ]
Haddad, Sandra [1 ]
Tang, Ping [1 ]
机构：
[1] Loyola Univ Med Ctr, Maywood, IL 60153 USA
[2] Mayo Clin, Rochester, MN USA
[3] Loyola Pathol, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
122
引用
收藏
页码：S146 / S148
页数：3
相关论文
共 50 条
  • [31] HER2 Positive Breast Cancers with Progression
    Solanki, Malvika
    Chitambar, Christopher
    Jorns, Julie
    MODERN PATHOLOGY, 2019, 32
  • [32] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2019, 99
  • [33] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Yao-Shan Fan
    Carmen E. Casas
    Jinghong Peng
    Melanie Watkins
    Lynn Fan
    Jennifer Chapman
    Offiong Francis Ikpatt
    Carmen Gomez
    Wei Zhao
    Isildinha M. Reis
    Breast Cancer Research and Treatment, 2016, 155 : 457 - 462
  • [34] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Fan, Yao-Shan
    Casas, Carmen E.
    Peng, Jinghong
    Watkins, Melanie
    Fan, Lynn
    Chapman, Jennifer
    Ikpatt, Offiong Francis
    Gomez, Carmen
    Zhao, Wei
    Reis, Isildinha M.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 457 - 462
  • [35] The comparison of HER2 low and HER2 0 in ductal carcinoma in situ (DCIS) for breast cancer
    Kureyama, Nari
    Kusudo, Maho
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Nozawa, Kazuki
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    MODERN PATHOLOGY, 2019, 32
  • [37] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [38] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Calmodulin binds HER2 and modulates HER2 signaling
    White, Colin D.
    Li, Zhigang
    Sacks, David B.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2011, 1813 (05): : 1074 - 1082
  • [40] A Comparative Analysis of the Value of Her2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of Her2 "LOW" Breast Cancers
    Bhardwaj, Swati
    Kandel, Avi
    Collins, Victoria
    Zeizafoun, Nebras
    Zeng, Jennifer
    Jaffer, Shabnam
    LABORATORY INVESTIGATION, 2023, 103 (03) : S103 - S103
12345